ReviewFrontiers in endocrinology2026
The lipotoxicity-ferroptosis axis in the transition from insulin resistance to type 2 diabetes: mechanistic integration and therapeutic opportunities.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance is an early feature of type 2 diabetes mellitus (T2DM), but progression to persistent hyperglycemia requires failure of pancreatic β-cell compensation. Lipotoxicity develops when adipose storage and oxidative capacity are exceeded, increasing fatty-acid flux and accumulation of ceramides, diacylglycerols, and oxidizable phospholipids in liver, skeletal muscle, and pancreatic islets. Ferroptosis is an iron-dependent form of regulated cell death driven by uncontrolled phospholipid peroxidation. Lipotoxicity can increase ferroptosis susceptibility by enriching polyunsaturated fatty acid-containing membrane phospholipids, increasing organelle-derived reactive oxygen species, and weakening system Xc--glutathione-glutathione peroxidase 4 defense; however, expansion of a redox-active iron pool is a distinct, cell- and context-dependent requirement. We organize these processes into a four-state working model spanning metabolic compensation, systemic lipid overflow and insulin resistance, ferroptosis sensitization, and β-cell decompensation. This is a non-obligate conceptual trajectory rather than a universally recognized clinical sequence. Evidence is strongest in pancreatic β-cell and liver models; direct skeletal-muscle causality is limited, and a causal role in human T2DM has not been established. Ferroptosis also has cell-specific effects: protecting β cells may be beneficial, whereas ferroptotic removal of selected inflammatory or lipid-storing cell populations can improve metabolic outcomes in some models. Upstream lipid unloading through weight loss and established metabolic treatments has the greatest clinical maturity. ACSL4/LPCAT3-dependent membrane remodeling, GPX4-centered defense, ferritinophagy, labile iron, parallel suppressor systems, and targeted delivery remain predominantly preclinical or candidate approaches. Multidimensional biomarker panels may support future mechanistic studies, but no individual marker or composite panel is currently validated to diagnose ferroptosis or a ferroptosis-susceptible phenotype in T2DM. The lipotoxicity-ferroptosis axis should therefore be viewed as a testable, tissue-specific amplifier rather than a universal or solitary cause of T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.